Table 2.
Change in evidence components, between and within evidence sources, in the overall sample and in a subgroup of randomized controlled trials and observational studies usable for quantitative evidence synthesisa
| Overall sample (n = 139)b | COVID-NMA subgroup (n = 25)a | |||||||
|---|---|---|---|---|---|---|---|---|
| Change between or within at least one evidence source pair (n = 139) | First to latest preprint version (n = 91) | First preprint version to journal article (n = 66) | Latest preprint version to journal article (n = 18) | Change between or within at least one evidence source pair (n = 25) | First to latest preprint version (n = 18) | First preprint version to journal article (n = 15) | Latest preprint version to journal article (n = 7) | |
| Change in at least 1 evidence component | 63 (45) | 35 (38) | 36 (55) | 8 (44) | 15 (60) | 8 (44) | 12 (86) | 3 (43) |
| Change in study results | 42 (30) | 23 (25) | 25 (38) | 6 (33) | 10 (40) | 5 (28) | 9 (64) | 3 (43) |
| Change in risk of bias assessment | – | – | – | – | 5 (20) | 1 (6) | 4 (27) | 1 (14) |
| Change in abstract conclusion | 33 (24) | 18 (20) | 19 (29) | 3 (17) | 8 (32) | 5 (28) | 5 (36) | 1 (14) |
aIncludes studies used in quantitative evidence synthesis and GRADE development in the COVID-NMA project (randomized controlled trials; interrupted time-series, non-randomized studies using causal inference analysis or multivariable regression adjustment, including at least 150 incident users), with multiple evidence sources or evidence source versions. For more information see: https://covid-nma.com/emulated/
bIncludes the studies in the COVID-NMA subgroup